IP Group

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Founded in Philadelphia in 2018, Innervace is a regenerative therapy company focused on developing implantable tissue-engineered brain pathways for neurodegenerative disorders. Its lead product is a tissue-engineered nigrostriatal pathway designed to mimic the lost pathway in Parkinson's patients, providing potential disease-modifying therapies.

Kynos Therapeutics develops novel therapies targeting Kaiser-Meyer-Olkin (KMO), a key enzyme involved in inflammation, immunity, and metabolism. Its focus is on indications with unmet medical needs.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Oxular is a clinical-stage company developing innovative retinal therapeutics. It focuses on transforming the treatment of retinal diseases by offering tissue-specific drug delivery solutions to address unmet patient needs, such as age-related macular degeneration and diabetic macular edema.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Founded in 2017, Kira Biotech is an Australian biotechnology company dedicated to developing novel immunomodulatory compounds. Its lead candidate, KB312, is a first-in-class monoclonal antibody targeting activated immune cells to induce immune tolerance and treat immune system disorders such as rheumatoid arthritis and systemic lupus erythematosus.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.

Istesso is a biotechnology company focused on drug discovery and development in the field of immunometabolism. Founded in 2017, the company aims to create disease-resolving therapies for chronic autoimmune and inflammatory conditions, including rheumatoid arthritis and multiple sclerosis. Istesso's pipeline consists of both pre-clinical and clinical assets that work by reprogramming metabolic processes to address these complex diseases. By specializing in immune metabolism, Istesso is dedicated to providing innovative solutions that enhance the diagnosis and treatment of serious health conditions, ultimately aiming to improve patient outcomes.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Spirea Ltd is a healthcare technology company based in Harrogate, United Kingdom, focused on developing innovative antibody drug conjugates (ADCs) for cancer treatment. Established in 2015, Spirea has created a smart polymer platform that enhances the controlled delivery of drug combinations, aiming to maximize the clinical efficacy of therapies. The company's flexible approach to ADC design allows for a greater amount of drug payload to be precisely targeted at tumor cells, increasing therapeutic effects while significantly minimizing adverse side effects. This advancement enables healthcare providers to offer well-tolerated treatment options for a variety of cancer types, ultimately improving patient outcomes.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Lorem Therapeutics is focusing on development early stage therapeutics in the phase between initial drug discovery and when a treatment begins review by the FDA for status as an Investigational New Drug. The company will use the funding “to accelerate and enhance our drug discovery efforts around critical cancer indications,” Slusher said in a statement.

Spirea Ltd is a healthcare technology company based in Harrogate, United Kingdom, focused on developing innovative antibody drug conjugates (ADCs) for cancer treatment. Established in 2015, Spirea has created a smart polymer platform that enhances the controlled delivery of drug combinations, aiming to maximize the clinical efficacy of therapies. The company's flexible approach to ADC design allows for a greater amount of drug payload to be precisely targeted at tumor cells, increasing therapeutic effects while significantly minimizing adverse side effects. This advancement enables healthcare providers to offer well-tolerated treatment options for a variety of cancer types, ultimately improving patient outcomes.

Akamis Bio is a clinical-stage oncology company dedicated to improving cancer patient outcomes through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops therapeutics that enable the immune system to recognize and clear solid tumors.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Avacta Group specializes in life science technologies and reagents for applications ranging from drug discovery to diagnostics. It operates through Analytical and Animal Health segments, offering tools and contract services for protein analysis in biopharmaceutical development and veterinary diagnostics.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Intelligent Ultrasound Group is a company specializing in the development, marketing, and distribution of medical training simulators and clinical ultrasound software. Based in Cardiff, United Kingdom, it offers a range of innovative products designed to enhance the quality and reliability of medical ultrasound. Its clinical AI software products, including ScanNav Audit, ScanNav AutoCapture, and ScanNav AnatomyGuide, provide real-time support and automation in ultrasound procedures, such as fetal anomaly scans and the identification of key anatomical structures. The company's training simulators, such as ScanTrainer for obstetrics and gynecology, HeartWorks for cardiac training, and BodyWorks for emergency medicine, are widely used to educate medical professionals. Intelligent Ultrasound Group, which was founded in 2004 and formerly known as MedaPhor Group, has a significant presence in the United Kingdom, North America, and other international markets.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Exonate is a biotechnology company focused on developing small molecule drugs that modulate alternative messenger RNA splicing. It specializes in ophthalmology, with a primary focus on treating diabetic retinopathy and diabetic macular oedema (DMO), as well as wet age-related macular degeneration (wAMD). The company's lead program aims to provide superior efficacy through topical agents in preclinical models of wAMD.

Ubiquigent Limited is a biotechnology company based in Dundee, United Kingdom, founded in 2009. It specializes in the development and supply of high-quality reagents, kits, and drug discovery assay development services, focusing on the ubiquitin and ubiquitin-like signaling systems. The company provides protein degradation-focused drug discovery services and designs novel deubiquitylase (DUB) enzyme inhibitors as potential therapeutics for addressing unmet medical needs. Ubiquigent collaborates with both academic and pharmaceutical researchers, supporting fundamental scientific discovery and the exploration of innovative drug candidates targeting DUBs. Its hybrid business model emphasizes the generation of intellectual property while maintaining an internal pipeline of drug discovery programs aimed at optimizing compounds for critical therapeutic areas.

Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, that specializes in the development of small molecule drugs aimed at treating cancer and immune/inflammatory disorders. Founded in 2005, the company focuses on designing innovative, molecular-targeted therapies. Its portfolio includes orally-active drugs such as KA2237, a dual-selective inhibitor of PI3K isoforms effective against hematological and solid tumors, and KA2507, which targets HDAC6 for tumors expressing PD-L1. By combining targeted therapy with immunotherapeutic activity, Karus Therapeutics aims to provide effective treatment options for a diverse range of cancers.

MedaPhor Limited is an e-learning company based in Cardiff, United Kingdom, that specializes in creating training products for postgraduate medical professionals. The company focuses on enhancing ultrasound examination techniques through its innovative simulation technology solutions. MedaPhor's offerings include Blue Phantom, which provides ultrasound phantoms for hands-on simulation training in gynaecology and obstetrics, and True Anatomy, an endovaginal training model designed for ultrasound simulation. Additionally, MedaPhor develops models for intrauterine pregnancy, ectopic pregnancy, and general pathology, contributing to the advancement of medical education and training. Established in 2004, MedaPhor aims to improve the skills and knowledge of healthcare practitioners through its comprehensive training solutions.

Clyde Biosciences is a developer of cardiac cell analysis solutions that provide human-relevant data to de-risk drug development. The company creates cell-based assays and analytics to reveal how drug compounds affect heart cells, enabling assessment of efficacy and potential cardiotoxicity in early research. Its offerings include cellOPTIQ, an optical action potential assay that measures drug effects on human cardiomyocytes, and XTENDSR, which quantifies drug-induced changes in cardiac sarcoplasmic reticulum function. By translating cellular responses into functional cardiomyocyte data, Clyde Biosciences supports pharmaceutical and biotechnology companies in identifying safety risks earlier and guiding molecule selection. Headquartered in Glasgow, United Kingdom, the company serves clients internationally and focuses on delivering human-relevant, mechanistic insights to improve the safety profile of new medicines.

Iksuda Therapeutics is a biotechnology company focused on developing next-generation biotherapeutics, specifically antibody-drug conjugates designed to treat challenging cancers, including those resistant to current therapies.

Activiomics Ltd. is a biotechnology company specializing in biomarker technology and phosphoproteomics solutions aimed at enhancing biomarker discovery and drug candidate profiling. The company has developed a patented mass spectrometry-based technology that facilitates the global quantitative analysis of phosphorylation sites, which are critical mediators of cellular processes. This technology, known as TIQUAS (Targeted In-depth QUAntification of cell Signalling), allows for the quantification of thousands of phosphorylation events from tissue samples. By identifying and quantifying proteins and phosphoproteins that correlate with disease progression and drug administration, Activiomics aims to transform the development of diagnostics and therapeutic strategies.

Crysalin Limited is a research and development company based in London, United Kingdom, founded in June 2007. It specializes in crysalin lattice technology, which has been developed from patented research conducted at the Oxford University Laboratory of Molecular Biophysics since 2002. The company's primary focus is on crysalins, a protein-based nanotechnology that significantly enhances protein structure determination, particularly for challenging macromolecular targets such as membrane proteins and flexible soluble proteins. By imposing order on these complex structures, crysalins enable advanced imaging techniques like X-ray and electron microscopy to accurately resolve three-dimensional molecular structures. In addition to protein structure determination, Crysalin's technology holds potential applications in biosensor development and optoelectronics, expanding its impact in the field of molecular research.

Iksuda Therapeutics is a biotechnology company focused on developing next-generation biotherapeutics, specifically antibody-drug conjugates designed to treat challenging cancers, including those resistant to current therapies.

Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, that specializes in the development of small molecule drugs aimed at treating cancer and immune/inflammatory disorders. Founded in 2005, the company focuses on designing innovative, molecular-targeted therapies. Its portfolio includes orally-active drugs such as KA2237, a dual-selective inhibitor of PI3K isoforms effective against hematological and solid tumors, and KA2507, which targets HDAC6 for tumors expressing PD-L1. By combining targeted therapy with immunotherapeutic activity, Karus Therapeutics aims to provide effective treatment options for a diverse range of cancers.

TheraGenetics was spun out of King's College London in April 2006. Their technology is based upon pharmacogenetics; the study of genetic factors involved in influencing an individual's response to drug treatments. The strong foundation of TheraGenetics stems from the founding team's long commitment to pharmacogenetics that has situated us at the cutting edge of personalised medicine. Under the umbrella of the Institute of Psychiatry at King's College London, the founding team translated 15 years of research into the commercial world by developing the first pharmacogenetic test for response prediction in psychiatry. In 2005, this test which focuses on the schizophrenia treatment clozapine, was successfully licensed by King's College London to a major UK laboratory who have successfully brought the test to market in 2006. Based on this achievement and the overwhelming enthusiasm for personalised medicine solutions, King's College London, the academic founders and the London based venture firm IPGroup PLC launched TheraGenetics in April 2006. TheraGenetics unique knowledge and experience in CNS disorders extends from the bench to the bedside. The ultimate clinical utility has been a priority consideration at all stages of their test development; their clinical team knows what is required at the patient care interface and they develop tests accordingly. The TheraGenetic's team has a threshold of knowledge and experience spanning the whole test development process that is now allowing us to rapidly advance their work in the field of pharmacogenetic response prediction.

Tissue Regenix Group is a medical technology company specializing in the development and commercialization of innovative products in the field of tissue engineering and regenerative medicine. Incorporated in 2006 and based in Garforth, United Kingdom, the company operates through several divisions, including BioSurgery, Orthopaedics & Dental, and Cardiac. Tissue Regenix's core technology, dCELL, involves a decellularization process that removes DNA and cellular material from biological tissues, allowing for repopulation with the patient’s own cells, thus minimizing rejection risks and enhancing natural healing. The company offers a range of products, including DermaPure, a decellularized dermal allograft for various medical applications, and BioRinse, a natural bone filler that promotes native bone growth. Other notable products include SurgiPure XD for hernia repair and OrthoPure XT, a scaffold for tissue regeneration. With a commitment to addressing complex clinical needs, Tissue Regenix is positioned as a leader in regenerative medicine, with a strong focus on the U.S. market.